

# PREVENTING FATAL OPIOID OVERDOSE AMONG YOUR PATIENTS

Opioid overdose fatalities have been steadily increasing for the last 15 years. Each year more people die from overdose than from motor vehicle crashes<sup>2</sup>.

# **EDUCATE YOUR PATIENTS: OVERDOSE PREVENTION MESSAGES**

#### Keep yourself safe

- •Only take opioids prescribed to you and as directed
- •Make sure your prescribers know of all medications you are taking
- •Don't mix opioids with alcohol or other sedatives
- •Abstinence lowers tolerance take less opioid upon restart
- •If you are not taking opioids safely, we can help you find treatment

#### Keep your family and household safe

- •Teach friends and family how to respond to overdose with Naloxone
- •Store all medication in a safe and secure place




### PRESCRIBE TO SAVE LIVES

Increasing access to Naloxone for at-risk individuals and their families is supported by the American Medical Association, American Pharmacists Association, American Society of Addiction Medicine, the World Health Organization and the Office for National Drug Control Policy.<sup>3-7</sup> Also see: www.prescribetoprevent.org

## **ASSESS OVERDOSE RISK**





#### BUPRENORPHINE TRAINING & CERTIFICATION

- •Ohio's Opiate Project ECHO™: Expanding Access to Medication Assisted Treatment: http://workforce.mha.ohio.gov/Workforce-Development/Health-Professionals/Opiate-Project-ECHO-CMEs
- •Data 2000 Prescriber Training for Medication-Assisted-Treatment: http://workforce.mha.ohio.gov/Workforce-Development/Health-Professionals/Cures-Act-Prescriber-MAT-Training
- •eTraining and Practice Tools: www.buppractice.com

# OFFER BUPRENORPHINE TREATMENT

- •Highly effective in reducing illicit opioid use<sup>8,9</sup>
- •Associated with reduced overdose death rates<sup>10</sup>
- •Very low risk for overdose
- •Decreased risk of abuse
- ·Available in ambulatory care settings

|   | INTRA-NASAL   | INTRA-NASAL RELEASED IN 2016   | IM   | AUTO-IM   |
|---|---|--|--|---|
| STRENGTH                                | Naloxone 1mg/1mL  | Naloxone 4mg/0.1mL   | Naloxone 0.4mg/1mL   | Naloxone 0.4mg/1mL  |
| QUANTITY                                | Two 2 mL prefilled<br>Luer-Jet™Luer-Lock<br>needleless syringe PLUS 2<br>mucosalatomizer devices<br>(MAD-300) | #1 two pack  | Two single-use 1 mL vials  | #1 two pack   |
| SIG<br>for suspected<br>opioid overdose | Spray 1 mL (half of the syringe) into each nostril. Repeat after 2-3 minutes if no or minimal response.       | Spray full dose into one nostril. Repeat into other nostril after 2-3 minutes if no or minimal response. | Inject 1 mL in shoulder<br>or thigh. Repeat after 2-3<br>minutes if no or<br>minimal response. | Use as directed by voice-<br>prompt. Press black side<br>firmly on outer thigh.<br>Repeat after 2-3 minutes if<br>no or minimal response. |
| REFILLS                                 | Two   | Two  | Two  | Two   |



- Neww.cdc.gov/nchg/deaths.htm

  2 www.cdc.gov/nchg/deaths.htm

  3 Help Save Lives: Increase access to naloxone. AMA Task Force to Reduce Opioid Abuse. September 2015. www.ama-assn.org

  4 APhA Policy: Controlled Substances and Other Medications with the Potential for Abuse and Use of Opioid Reversal Agents. (japha 54(4) July/August 2014)

  (reviewed 2015). www.pharmacist.com

  5 Geof Naloxone for the Prevention of Drug Overdose Deaths. Adoption date April 15, 2010, rev. August 16, 2014. www.asam.org

  6 Opioid Overdose: preventing and reducing opioid overdose mortality. Discussion paper UNODC/WHO 2013. www.unodc.org

  7 Fact Sheet: Preventing, Treating, and Surviving Overdose. Office of National Drug Control Policy, Office of Public Affairs. August 28, 2013. www.whitehouse.gov

  8 Johnson RR, Jaffe JH, Fuduala PJ. A controlled trial of buprenorphine treatment for opioid dependence. IAMA 1992 May 27;267(20):2750-5.

  9 Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 2015 Nov 24.

  10 Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychattry 2015 Oct;2(10):901-8.

**BROUGHT TO YOU BY:** 



Used with permission from the Prescribe to Save Lives project (NIDA grant 7R01DA038082; PI: Friedmann/Rich).

Learn More | PrescribeToPrevent.org

Visit **TakeChargeOhio.org** to find more tips and resources on safe medication and prescribing practices.